ArticleHuman vaccines & immunotherapeutics2025

Cost-effectiveness of trastuzumab deruxtecan as a second-line treatment for HER2-mutant advanced non-small cell lung cancer.

Qi Cai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.